First-Ever ‘Basket Study’ of Cancer Mutations Shows Positive Results

Clinical Trials Advisor
A A
A first-of-its-kind “basket study” of responses to Daiichi Sankyo and Genentech’s Zelboraf on a host of cancer mutations is showing positive results, Memorial Sloan Kettering Cancer Center researchers report.

To View This Article:

Login

Subscribe To Clinical Trials Advisor